GEN - Genetic Engineering and Biotechnology News10d
Tolerogenic Therapies Retrain the Immune System
COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases.
Argenx Benefits From Multiple Approved Indications of Vyvgart and Strong Uptake
Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...
HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
The Bromsgrove Standard5d
Bromsgrove man welcomes historic medical milestone as plasma from Worcestershire blood donors is used in life-saving medicine
A MAN in Bromsgrove with a rare autoimmune disease has welcomed news of an historic medical milestone which has seen blood ...
No-Moat UCB Remains Focused on Strong Commercial Launches of New Drugs to Offset Generic Erosion
UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...
106 medical conditions that could cost drivers £1,000 for breaking DVLA rule
Drivers are being warned that failure to inform the DVLA about a health diagnosis, and any subsequent changes in health, can ...
BioSpace22d
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
The company is running three Phase II programs right now in primary biliary cholangitis, diabetes and myasthenia gravis. COUR will be facing some major Big Pharma peers in myasthenia; Argenx’s Vyvgart ...